Literature DB >> 12209665

Endoscopic ultrasound-guided fine-needle aspiration biopsy: a study of 103 cases.

David C Chhieng1, Darshana Jhala, Nirag Jhala, Isam Eltoum, Victor K Chen, Selwyn Vickers, Martin J Heslin, C Mel Wilcox, Mohamad A Eloubeidi.   

Abstract

BACKGROUND: Endoscopic ultrasound (EUS) provides detailed imaging of both intramural and extramural structures within the abdomen and mediastinum. However, EUS is limited in its ability to differentiate an inflammatory/reactive process from a malignancy. Fine-needle aspiration biopsy (FNAB), coupled with EUS, allows for the sampling of the target lesion under ultrasound guidance in real time. To better evaluate the clinical utility and efficiency of EUS-FNAB, a retrospective analysis of the first 103 EUS-FNABs performed at our institute was undertaken.
METHODS: EUS-FNABs was performed in 80 patients with 103 lesions. Both air-dried and alcohol-fixed smears were prepared and stained with Diff-Quik (American Scientific Products, McGraw Park, IL) and Papanicolaou stains, respectively. In addition, ThinPrep slides (Cytyc, Boxborough, MA) and cell blocks, when additional material was available, were also prepared. Immunohistochemical stains were performed on cell blocks wherever required. Cytologic diagnoses were then correlated with the final diagnoses. The latter was based on histologic examination of biopsies/resected pathology materials (n = 54) and clinical follow up (n = 48). Follow-up information was not available for one lesion.
RESULTS: Of 103 EUS-FNABs, 42 FNABs were from the pancreas, 38 from the lymph nodes (10 mediastinal and 28 intraabdominal), 10 from the gastrointestinal tract, 7 from the liver, 4 from the adrenal gland, 1 from the biliary tract, and 1 from a retroperitoneal mass. The mean number of passes to obtain diagnostic materials was 3.3. Of 103 EUS-FNABs, 45, 9, 6, and 37 were reported as malignant, suspicious, atypical, and benign, respectively. Six FNABs were nondiagnostic. The authors did not encounter any false-positive cases. There were three false-negative cases (two pancreatic carcinomas and one gastrointestinal stromal tumor of the stomach). No complications were encountered. The sensitivity, specificity, and accuracy were 71%, 100%, and 81%, respectively. If the FNABs that were classified as suspicious were considered as malignant, the sensitivity, specificity, and accuracy were 86%, 100%, and 91%, respectively.
CONCLUSIONS: EUS-FNAB is a safe and accurate diagnostic procedure for the evaluation of intramural and extramural lesions of the gastrointestinal tract. In the majority of cases, it obviates the need for more invasive diagnostic procedures to obtain a tissue diagnosis. Copyright 2002 American Cancer Society.DOI 10.1002/cncr.10714

Entities:  

Mesh:

Year:  2002        PMID: 12209665     DOI: 10.1002/cncr.10714

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  28 in total

1.  Transjugular Liver Biopsy in a Multiple Myeloma Patient with Hepatomegaly, Portal Hypertension and "Miliary" Liver Lesions: A Case Report.

Authors:  Adrian J Gonzalez-Aguirre; Oscar Lin; Christina Cho; Alexander M Lesokhin; Majid Maybody
Journal:  J Gastrointest Dig Syst       Date:  2016-02-10

Review 2.  Endoscopic Ultrasonography-Guided Biopsy for Differentiation of Benign and Malignant Pelvic Lesions: A Systematic Review and Meta-Analysis.

Authors:  Chaoqun Han; Rong Lin; Jun Liu; Xiaohua Hou; Wei Qian; Zhen Ding
Journal:  Dig Dis Sci       Date:  2015-09-04       Impact factor: 3.199

3.  Endosonographer's macroscopic evaluation of EUS-FNAB specimens after interactive cytopathologic training: a single-center prospective validation cohort study.

Authors:  Hong Joo Kim; Yoon Suk Jung; Jung Ho Park; Dong Il Park; Yong Kyun Cho; Chong Il Sohn; Woo Kyu Jeon; Byung Ik Kim; Kyu Yong Choi; Seungho Ryu
Journal:  Surg Endosc       Date:  2016-01-07       Impact factor: 4.584

4.  Endoscopic ultrasound guided fine needle aspiration of non-pancreatic lesions: an institutional experience.

Authors:  Dipti Anand; Julieta E Barroeta; Prabodh K Gupta; Michael Kochman; Zubair W Baloch
Journal:  J Clin Pathol       Date:  2007-01-12       Impact factor: 3.411

5.  Impact of endoscopic ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses.

Authors:  Julio Iglesias-Garcia; Enrique Dominguez-Munoz; Antonio Lozano-Leon; Ihab Abdulkader; Jose Larino-Noia; Jose Antunez; Jeronimo Forteza
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

6.  Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.

Authors:  Hyunki Kim; Karri D Folks; Lingling Guo; Jeffery C Sellers; Naomi S Fineberg; Cecil R Stockard; William E Grizzle; Donald J Buchsbaum; Desiree E Morgan; James F George; Kurt R Zinn
Journal:  Mol Imaging       Date:  2011-06       Impact factor: 4.488

7.  Is it time to take a pass on the increased number of passes in EUS-FNA?

Authors:  Shantel Hébert-Magee; Robert H Hawes; Shyam Varadarajulu
Journal:  Dig Dis Sci       Date:  2013-11       Impact factor: 3.199

Review 8.  Endoscopic ultrasound: it's accuracy in evaluating mediastinal lymphadenopathy? A meta-analysis and systematic review.

Authors:  Srinivas-R Puli; Jyotsna Batapati Krishna Reddy; Matthew-L Bechtold; Jamal-A Ibdah; Daphne Antillon; Shailender Singh; Mojtaba Olyaee; Mainor-R Antillon
Journal:  World J Gastroenterol       Date:  2008-05-21       Impact factor: 5.742

9.  Does onsite cytotechnology evaluation improve the accuracy of endoscopic ultrasound-guided fine-needle aspiration biopsy?

Authors:  Fahad Alsohaibani; Safwat Girgis; Gurpal Singh Sandha
Journal:  Can J Gastroenterol       Date:  2009-01       Impact factor: 3.522

10.  Inadequate fine needle aspiration biopsy samples: pathologists versus other specialists.

Authors:  G S Gomez-Macías; R Garza-Guajardo; J Segura-Luna; O Barboza-Quintana
Journal:  Cytojournal       Date:  2009-06-18       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.